FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
ECG Modernization Project Links CardioComm Solutions to the FAA Aviation Medical Examiner (AME) Community
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed that it has been listed as a cloud services provider under the launch of the Federal Aviation Administration (“FAA”) Civil Aerospace Medical Institute ECG Modernization project. The specific product involved is the Company’s GlobalCardio™ 12 Lead ECG solution (“GC12”).
“During the fall of 2013, the Aerospace Medical Certification Division, in partnership with FAA's Office of Information Technology, began working to replace the existing FAA ECG system. CardioComm Solutions was informed in late June 2014 of the decision by the FAA to be listed as a cloud-based ECG service provider under their initiative for the digital modernization of their existing system. The listing of our Company, as well as those of ECG equipment providers, is not an endorsement by the FAA. That being said, we did undergo a review by the FAA IT Support Group and our 12 lead solution remains the only one identified as a cloud-based, virtual ECG service to render ECG reports in a PDF format for their Airman Medical Certification Subsystem (“AMCS”) workstations,” said Simi Grosman, member of the Company’s Board.
The GC12 solution is an FDA cleared, Health Canada approved and CE marked technology and ECG service and has also been used in multiple clinical trials. “Due to GC12’s global regulatory approvals and adherence to PIPEDA and HIPPA requirements, this is a logical offering to FAA AMEs regardless of their geographic distribution. The system offers a cost effective solution that can be used in busy clinics and in mobile applications, and can provide a per ECG, fixed purchase cost or annual licensing option, depending on the business needs of the AME,” said Etienne Grima, Chief Executive Officer for CardioComm Solutions. “With our capacity to integrate our software with several ECG device manufacturer 12 lead ECG machines, the GC12 offering will provide needed flexibility for AMEs to move into compliance with the FAA directed changes related to the recording and uploading of ECG reports into their proprietary medical records system.”
The ECG Modernization FAA website lists over 3,200 AMEs registered through the FAA globally who act as representatives of the FAA Administrator and are authorized by law to examine, test and/or make inspections necessary to issue airman or aircraft certificates. The new system was released August 27 and AMEs will have until September 30 to make the transition, after which date the current ECG system will be deactivated permanently.
“This listing marks a material opportunity as it introduces CardioComm Solutions into a highly regulated environment. The FAA Civil Aerospace Medical Institute (“CAMI”) is the medical certification, research, education and occupational health wing of the FAA's Office of Aerospace Medicine whose goal is to enhance aviation safety. This is but one of several phases of our planned market entry strategy for the US government and defense agencies,” closed Etienne Grima.
More information regarding the HeartCheck™ products and SMART Monitoring solutions is available at the Company’s web site www.cardiocommsolutions.com.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of